Jazz Pharmaceuticals plc Increase (Decrease) in Contract with Customer, Liability
Jazz Pharmaceuticals plc (JAZZ) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-02-26
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for fiscal 2023 was -$463.00K.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for fiscal 2022 was -$2.09M.
- Jazz Pharmaceuticals plc increase (decrease) in contract with customer, liability for fiscal 2021 was -$2.31M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | -$4.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | -$4.00K derived: sum of 3 quarters · filed 2025-02-26 | -$4.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | -$4.00K derived: sum of 2 quarters · filed 2025-02-26 | -$4.00K derived: sum of 3 quarters · filed 2025-02-26 | -$4.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$4.00K derived: sum of 2 quarters · filed 2025-02-26 | -$4.00K derived: sum of 3 quarters · filed 2025-02-26 | -$463.00K 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$459.00K 10-Q · filed 2024-11-07 | -$982.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$459.00K 10-Q · filed 2024-08-01 | -$982.00K derived: sum of 3 quarters · filed 2025-02-26 | -$1.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$459.00K 10-Q · filed 2024-05-02 | -$982.00K derived: sum of 2 quarters · filed 2025-02-26 | -$1.50M derived: sum of 3 quarters · filed 2025-02-26 | -$2.03M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$1.05M derived: sum of 2 quarters · filed 2025-02-26 | -$1.57M derived: sum of 3 quarters · filed 2025-02-26 | -$2.09M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$523.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.05M derived: sum of 2 quarters · filed 2023-11-08 | -$1.57M 10-Q · filed 2023-11-08 | -$2.27M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$524.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.05M 10-Q · filed 2023-08-09 | -$1.74M derived: sum of 3 quarters · filed 2024-02-28 | -$2.44M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$523.00K 10-Q · filed 2023-05-10 | -$1.22M derived: sum of 2 quarters · filed 2024-02-28 | -$1.92M derived: sum of 3 quarters · filed 2024-02-28 | -$2.19M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.39M derived: sum of 2 quarters · filed 2024-02-28 | -$1.67M derived: sum of 3 quarters · filed 2024-02-28 | -$2.31M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$697.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$971.00K derived: sum of 2 quarters · filed 2022-11-09 | -$1.61M 10-Q · filed 2022-11-09 | -$2.79M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$274.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$911.00K 10-Q · filed 2022-08-03 | -$2.09M derived: sum of 3 quarters · filed 2023-03-01 | -$3.27M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$637.00K 10-Q · filed 2022-05-04 | -$1.82M derived: sum of 2 quarters · filed 2023-03-01 | -$3.00M derived: sum of 3 quarters · filed 2023-03-01 | -$4.18M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$2.36M derived: sum of 2 quarters · filed 2023-03-01 | -$3.54M derived: sum of 3 quarters · filed 2023-03-01 | -$4.72M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$2.36M derived: sum of 2 quarters · filed 2021-11-09 | -$3.54M 10-Q · filed 2021-11-09 | -$4.72M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$2.36M 10-Q · filed 2021-08-03 | -$3.54M derived: sum of 3 quarters · filed 2022-03-01 | -$4.72M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$1.18M 10-Q · filed 2021-05-04 | -$2.36M derived: sum of 2 quarters · filed 2022-03-01 | -$3.54M derived: sum of 3 quarters · filed 2022-03-01 | -$4.72M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$2.36M derived: sum of 2 quarters · filed 2022-03-01 | -$3.54M derived: sum of 3 quarters · filed 2022-03-01 | -$5.41M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | -$2.36M derived: sum of 2 quarters · filed 2020-11-02 | -$4.23M 10-Q · filed 2020-11-02 | -$6.11M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$3.05M 10-Q · filed 2020-08-04 | -$4.93M derived: sum of 3 quarters · filed 2021-02-23 | -$6.80M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | -$1.87M 10-Q · filed 2020-05-05 | -$3.75M derived: sum of 2 quarters · filed 2021-02-23 | -$5.62M derived: sum of 3 quarters · filed 2021-02-23 | -$7.50M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | -$3.75M derived: sum of 2 quarters · filed 2021-02-23 | -$5.62M derived: sum of 3 quarters · filed 2021-02-23 | -$7.50M 10-K · filed 2021-02-23 |
| 2018-09-30 | -$1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$3.75M derived: sum of 2 quarters · filed 2019-11-05 | -$5.62M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$3.75M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$1.88M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $21.01M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | -$1.31M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |